Terms: = Lung cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
876 results:
1. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal cancer Cell Lines Regardless of HPV Status.
Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
[TBL] [Abstract] [Full Text] [Related]
2. SH003 Enhances the Anti-cancer Effects of Dabrafenib on lung cancer Harboring
Choi YJ; Chung YH; Lee K; Jeong M; Ko SG
Anticancer Res; 2024 May; 44(5):1905-1913. PubMed ID: 38677764
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of
Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
[TBL] [Abstract] [Full Text] [Related]
4. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
5. Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell lung cancer in Administrative Claims Databases.
Patel SP; Wang R; Zhou SQ; Sheinson D; Johnson A; Lee JS
JCO Clin Cancer Inform; 2024 Mar; 8():e2300165. PubMed ID: 38502111
[TBL] [Abstract] [Full Text] [Related]
6. The outcome in patients with braf-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract] [Full Text] [Related]
7. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating braf Mutation: A First in Non-Small Cell lung cancer.
Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
[TBL] [Abstract] [Full Text] [Related]
8. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
9. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the braf V600E mutation with high expression of PD-L1: A case report.
Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
[TBL] [Abstract] [Full Text] [Related]
10. Prognosis of non-small cell lung cancer with postoperative regional lymph node recurrence.
Ohtaki Y; Nagashima T; Okano N; Kubo N; Ohtaka T; Sunaga N; Sakurai R; Miura Y; Nakazawa S; Kawatani N; Yazawa T; Yoshikawa R; Narusawa E; Shirabe K
Thorac Cancer; 2024 Apr; 15(11):859-866. PubMed ID: 38414316
[TBL] [Abstract] [Full Text] [Related]
11. Primary endobronchial melanoma: a case report and clinical management indications.
Barisione E; Boutros A; Mora M; Spagnolo F; Tanda ET; Genova C; Tagliabue E
BMC Pulm Med; 2024 Feb; 24(1):97. PubMed ID: 38402179
[TBL] [Abstract] [Full Text] [Related]
12. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
Raskova Kafkova L; Mierzwicka JM; Chakraborty P; Jakubec P; Fischer O; Skarda J; Maly P; Raska M
Front Immunol; 2024; 15():1342086. PubMed ID: 38384472
[TBL] [Abstract] [Full Text] [Related]
13. Targeting MEK in non-small cell lung cancer.
Lara MS; Blakely CM; Riess JW
Curr Probl Cancer; 2024 Apr; 49():101065. PubMed ID: 38341356
[TBL] [Abstract] [Full Text] [Related]
14. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
[TBL] [Abstract] [Full Text] [Related]
15. [Considering Recurrence Prevention Regimen for Colorectal cancer Patients with Hyperammonemia Caused by Chemotherapy Containing 5-Fluorouracil].
Aomatsu N; Tsujio G; Aomatsu K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1851-1853. PubMed ID: 38303229
[TBL] [Abstract] [Full Text] [Related]
16. [Progress of braf Gene Alteration in Non-small Cell lung cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract] [Full Text] [Related]
17. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K; Mizugaki H; Yokoo K; Kobayashi M; Kawashima Y; Kimura N; Yokouchi H; Kikuchi H; Sumi T; Kawai Y; Kobashi K; Morita R; Ito K; Kitamura Y; Minemura H; Nakamura K; Aso M; Honjo O; Tanaka H; Takashina T; Tsurumi K; Sugisaka J; Tsukita Y; Konno S; Oizumi S
Cancer Sci; 2024 Apr; 115(4):1273-1282. PubMed ID: 38287788
[TBL] [Abstract] [Full Text] [Related]
18. A phase 1 study of triple-targeted therapy with braf, MEK, and AKT inhibitors for patients with braf-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
19. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
[No Abstract] [Full Text] [Related]
20. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
Odintsov I; Sholl LM
Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
[TBL] [Abstract] [Full Text] [Related]
[Next]
